Trial of Psilocybin versus Escitalopram for Depression
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. METHODS: In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a 6-week period. Patients were assigned in a 1:1 ratio to receive two separate doses of 25 mg of psilocybin 3 weeks apart plus 6 weeks of daily placebo (psilocybin group) or two separate doses of 1 mg of psilocybin 3 weeks apart plus 6 weeks of daily oral escitalopram (escitalopram group); all the patients received psychological support. The primary outcome was the change from baseline in the score on the 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR-16; scores range from 0 to 27, with higher scores indicating greater depression) at week 6. There were 16 secondary outcomes, including QIDS-SR-16 response (defined as a reduction in score of >50%) and QIDS-SR-16 remission (defined as a score of ≤5) at week 6. RESULTS: A total of 59 patients were enrolled; 30 were assigned to the psilocybin group and 29 to the escitalopram group. The mean scores on the QIDS-SR-16 at baseline were 14.5 in the psilocybin group and 16.4 in the escitalopram group. The mean (±SE) changes in the scores from baseline to week 6 were -8.0±1.0 points in the psilocybin group and -6.0±1.0 in the escitalopram group, for a between-group difference of 2.0 points (95% confidence interval [CI], -5.0 to 0.9) (P = 0.17). A QIDS-SR-16 response occurred in 70% of the patients in the psilocybin group and in 48% of those in the escitalopram group, for a between-group difference of 22 percentage points (95% CI, -3 to 48); QIDS-SR-16 remission occurred in 57% and 28%, respectively, for a between-group difference of 28 percentage points (95% CI, 2 to 54). Other secondary outcomes generally favored psilocybin over escitalopram, but the analyses were not corrected for multiple comparisons. The incidence of adverse events was similar in the trial groups. CONCLUSIONS: On the basis of the change in depression scores on the QIDS-SR-16 at week 6, this trial did not show a significant difference in antidepressant effects between psilocybin and escitalopram in a selected group of patients. Secondary outcomes generally favored psilocybin over escitalopram, but the analyses of these outcomes lacked correction for multiple comparisons. Larger and longer trials are required to compare psilocybin with established antidepressants. (Funded by the Alexander Mosley Charitable Trust and Imperial College London's Centre for Psychedelic Research; ClinicalTrials.gov number, NCT03429075.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In two recent psilocybin clinical trials, ~95% of all volunteers were eliminated on the basis of exclusion criteria”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [8]
In the citing paper
“Amelioration of symptomatic depression in pilot studies of major depressive disorder, including those that compared psilocybin with escitalopram 8,9 and that investigated its use in treatment-resistant depression, 10 has suggested therapeutic potential for this agent.”
From Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (2022) · cites this paper as [9]
In the citing paper
“Studies have used inactive placebos (e.g., [17, 35]), active placebos whose effects considerably differ from the acute effects of serotonergic psychedelics (e.g., [15, 36, 37]), or doses of psilocybin presumably too low to maintain blinding (e.g., [38, 39])”
In the citing paper
“Contemporary clinical studies have involved one to three dosing sessions (e.g., [38, 39, 117])”
In the citing paper
“Research on MDD, anxiety and depressive symptoms associated with life-threatening cancer, and TRD showed the most robust evidence, supported by a non-randomized study 72 and several RCTs. 26,31-33,60,73-77”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [26]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Malhi, G. S., & Mann, J. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31948-2 · Cited by 4,099
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Self-citationEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Cited by
Items 401–500 of 1,001
Ippolito, A., Vasudevan, S. R., Hurley, S., Gilmour, G., Westhorpe, F. G., Churchill, G. C., & Sharp, T. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70109 · Cited by 25
“In particular, each of psilocybin , 5-methoxy-N,N-dimeth-yltryptamine ( 5-MeO-DMT ) and lysergic acid diethylamide ( LSD ) have progressed to clinical trials of depression and anxiety (Carhart-Harris et al., 2021; Holze et al., 2023; Reckweg et al., 2023).”
Emerging mechanisms of psilocybin-induced neuroplasticity
Sonda, S., Pendin, D., Comai, S., Martin, S. D., Manfredi, P., & Mattarei, A. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.08.012 · Cited by 24
Demin, K. A., Kupriyanova, O. V., Shevyrin, V. A., Derzhavina, K. A., Krotova, N. A., Ilyin, N. P., Kolesnikova, T. O., Galstyan, D. S., Kositsyn, Y. M., Khaybaev, A.-A. S., et al. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00123 · Cited by 23
Role of interaction of mGlu2 and 5-HT2A receptors in antipsychotic effects
Ibi, D. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173474 · Cited by 21
New Pharmacologic Approaches to the Treatment of Bipolar Depression
Keramatian, K., Chakrabarty, T., DuBow, A., Saraf, G., & Yatham, L. N. (2023) · Drugs · doi:10.1007/s40265-023-01872-x · Cited by 22
“(although a lack of placebo arm precluded drawing conclusions regarding efficacy), and another found significant reductions in depressive symptom severity compared with a waitlist (not placebo) control [111, 112].”
ResultThe development of psilocybin therapy for treatment-resistant depression: an update
Borissova, A., & Rucker, J. (2023) · BJPsych Bulletin · doi:10.1192/bjb.2023.25 · Cited by 23
“11 Masking to allocation (blinding) is largely impossible in clinical trials with psychedelics, introducing expectancy e ff ects.”
BackgroundWolfgang, A. S., & Hoge, C. W. (2023) · Current Psychiatry Reports · doi:10.1007/s11920-023-01446-4 · Cited by 25
Tolle, H. M., Farah, J. C., Mallaroni, P., Mason, N. L., Ramaekers, J. G., & Amico, E. (2024) · Network Neuroscience · doi:10.1162/netn_a_00349 · Cited by 23
Haniff, Z. R., Bocharova, M., Mantingh, T., Rucker, J., Velayudhan, L., Taylor, D. M., Young, A. H., Aarsland, D., Vernon, A. C., & Thuret, S. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108641 · Cited by 22
Harari, R., Chatterjee, I., Getselter, D., & Elliott, E. (2024) · iScience · doi:10.1016/j.isci.2024.109686 · Cited by 21
Mantas, I., Flais, I., Masarapu, Y., Ionescu, T. M., Frapard, S., Jung, F., Merre, P. L., Saarinen, M., Tiklová, K., Salmani, B. Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52429-9 · Cited by 21
Zhou, K., de Wied, D., Carhart-Harris, R. L., & Kettner, H. (2025) · PNAS Nexus · doi:10.1093/pnasnexus/pgae560 · Cited by 24
Self-citationDavis, J. M., Zamora, D., Horowitz, M. S., & Leucht, S. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1942455 · Cited by 21
“In phase 1 of the CLARITY study pimavanserin produced a considerable antidepressant effect and the direction of chance in the phase 3 study was toward benefit, but paradoxically Psilocybin which is a 5-HT2a agonist has been found to have an antidepressant effect [41,44,45].”
BackgroundKetamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Lengvenytė, A., Strumila, R., Olié, É., & Courtet, P. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.02.004 · Cited by 21
Levin, A. W., Nagib, P. B., Deiparine, S., Gao, T. Z., Mitchell, J. J., & Davis, A. K. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2022.103816 · Cited by 23
Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials
Herrmann, Z. M., Earleywine, M., Leo, J. A. D., Slabaugh, S., Kenny, T., & Rush, A. J. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2125467 · Cited by 21
“Indeed, recent publications have reported a correlation between higher scores on measures of “mystical experiences” and outcomes in MDD and TUD (Davis et al. 2020; Garcia-Romeu, Griffiths, and Johnson 2014).”
BackgroundPsychedelics: preclinical insights provide directions for future research
Gumpper, R. H., & Roth, B. L. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01567-7 · Cited by 21
Psychedelics and schizophrenia: a double-edged sword
Sapienza, J., Martini, F., Comai, S., Cavallaro, R., Spangaro, M., Gregorio, D. D., & Bosia, M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02743-x · Cited by 20
“…that should be tested fi rst we suggest psilocybin due to the large use in several treatment protocols, its safety and manageability (low potency compared to LSD) emerged in clinical trials on depression [9, 11, 12], and the pharmacodynamic pro fi le similar to the other psychedelic compounds [58].”
Schmitz, G. P., Chiu, Y.-T., Foglesong, M. L., Magee, S. N., MacKinnon, M., König, G. M., Kostenis, E., Hsu, L.-M., Shih, Y.-Y. I., Roth, B. L., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03611-0 · Cited by 31
Berlowitz, I., Torres, E. G., Maake, C., Wolf, U., & Martin-Söelch, C. (2023) · Plants · doi:10.3390/plants12020346 · Cited by 21
Classic Psychedelic Use and Current Meditation Practice
Simonsson, C., Chambers, R., Hendricks, P. S., Goldberg, S. B., Osika, W., Schlosser, M., Ryde, A., Christersson, E., & Simonsson, O. (2023) · Mindfulness · doi:10.1007/s12671-023-02103-w · Cited by 21
“, 2022, for potential risks), and may be effective in the treatment of various psychiatric disorders when administered in conjunction with therapy (e.g., Bogenschutz et al., 2022; Carhart-Harris et al., 2021).”
BackgroundConsumers prefer natural medicines more when treating psychological than physical conditions
Li, T., & Gal, D. (2023) · Journal of Consumer Psychology · doi:10.1002/jcpy.1371 · Cited by 23
Addiction specialists' attitudes toward psychedelics: A National Survey
Kim, A., & Suzuki, J. (2023) · American Journal on Addictions · doi:10.1111/ajad.13461 · Cited by 22
James, E., Erritzøe, D., Benway, T. A., Joel, Z., Timmermann, C., Good, M., Agnorelli, C., Weiss, B., Barba, T., Campbell, G., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1305796 · Cited by 23
Self-citationIs it now time to prepare psychiatry for a psychedelic future?
Nutt, D. J., CROME, I. B., & Young, A. H. (2024) · The British Journal of Psychiatry · doi:10.1192/bjp.2024.76 · Cited by 21
Self-citationWalther, R. F. E., & van Schie, H. T. (2024) · Psychoactives · doi:10.3390/psychoactives3030026 · Cited by 22
Ruffini, G., Castaldo, F., Lopez-Sola, E., Sanchez-Todo, R., & Vohryzek, J. (2024) · Entropy · doi:10.3390/e26110953 · Cited by 25
Psilocybin: From Psychiatric Pariah to Perceived Panacea
Fonzo, G. A., Wolfgang, A. S., Barksdale, B. R., Krystal, J. H., Carpenter, L. L., Kraguljac, N. V., Grzenda, A. L., McDonald, W. M., Widge, A. S., Rodríguez, C. I., et al. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230682 · Cited by 20
Modifying Informed Consent to Help Address Functional Unmasking in Psychedelic Clinical Trials
Matvey, M., Kelley, D. P., Bradley, E., Chiong, W., O’Donovan, A., & Woolley, J. D. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.4312 · Cited by 22
Lucido, M. J., & Dunlop, B. W. (2025) · Brain Sciences · doi:10.3390/brainsci15020161 · Cited by 24
“Notably, in a 59-patient RCT comparing psilocybin to an active antidepressant (escitalopram), the psychedelic did not demonstrate superiority for depressive symptoms on the primary outcome, though numerous secondary measures indicated greater benefits for patients in the PAT arm [156].”
Rediscovering Psilocybin as an Antidepressive Treatment Strategy
Zeiss, R., Gahr, M., & Graf, H. (2021) · Pharmaceuticals · doi:10.3390/ph14100985 · Cited by 32
“Over a six week period of treatment, no significant differences between psilocybin and escitalopram were observed regarding their antidepressant effects [81].”
BackgroundPsilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach
Agin-Liebes, G., & Davis, A. K. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_282 · Cited by 22
Will psilocybin lose its magic in the clinical setting?
Hayes, C., Wahba, M., & Watson, S. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253221090822 · Cited by 20
Reduced Precision Underwrites Ego Dissolution and Therapeutic Outcomes Under Psychedelics
Stoliker, D., Egan, G. F., & Razi, A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.827400 · Cited by 25
“This free Carhart-Harris and Friston, 2019), observations of increased entropy (Herzog et al., 2020) and theorized associations with increases in plasticity11 (Carhart-Harris, 2021; de Vos et al., 2021; Inserra et al., 2021).”
BackgroundChronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity
Huang, J. Y., Pham, M. M., Panenka, W. J., Honer, W. G., & Barr, A. M. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.891512 · Cited by 20
“Finally, while not necessarily a limitation, the present study used repeated, chronic treatment with psilocybin, whereas most human trials typically use a much small number of doses, often in combination with psychotherapy (43, 44).”
BackgroundResultBack to the Future — The Therapeutic Potential of Psychedelic Drugs
Lieberman, J. A. (2021) · New England Journal of Medicine · doi:10.1056/nejme2102835 · Cited by 20
Foffani, G. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad442 · Cited by 20
Validation of the imperial psychedelic predictor scale
Angyus, M., Osborn, S., Haijen, E. C. H. M., Erritzøe, D., Peill, J. M., Lyons, T., Kettner, H., & Carhart-Harris, R. L. (2024) · Psychological Medicine · doi:10.1017/s0033291724002204 · Cited by 22
“…’ s survey ( N = 741) (Haijen et al., 2018), a study of cere-mony usage of psychedelics ( N = 836) (Kettner et al., 2021), and two controlled trials ( N = 30 and N = 28) (Carhart-Harris et al., 2021; Lyons et al., in prep ) to assess the internal, convergent, and predictive validity of the IPPS.”
BackgroundSelf-citationKittur, M. E., M, L. A. B., Jones, B. D. M., Blumberger, D. M., Mulsant, B. H., Rosenblat, J. D., & Husain, M. I. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119952 · Cited by 19
Lewis, B. R., Hendrick, J., Byrne, K., Odette, M. M., Wu, C., & Garland, E. L. (2025) · PLoS Medicine · doi:10.1371/journal.pmed.1004519 · Cited by 21
“There is a precedent for using this tool in previous studies with psilocybin-assisted therapy [32].”
Immune-brain plasticity underpins stress and affective behaviors
Lee, J., & Wheeler, M. E. (2025) · Neuron · doi:10.1016/j.neuron.2025.11.020 · Cited by 21
Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review
Orsini, D. K., Wong, S., Luch, S. D. D., Chan, B., Vasudeva, S., Lovell, G. F. M., Le, G. H., Jones, B. D. M., Chisamore, N., Mollica, A., et al. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2026.0255 · Cited by 22
Heal, D. J., Gosden, J., Smith, S. L., & Atterwill, C. K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109375 · Cited by 20
Pizzi, S. D., Chiacchiaretta, P., Sestieri, C., Ferretti, A., ONOFRJ, M. C., Penna, S. D., Roseman, L., Timmermann, C., Nutt, D. J., Carhart-Harris, R. L., et al. (2023) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2023.03.009 · Cited by 20
Self-citationMcIntyre, R. S. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2253144 · Cited by 20
“In keeping with this conceptual framework, classic psyche-delics (e.g. psilocybin and its active moiety psilocin, LSD) have molecular, cellular, and circuit/network connectivity effects that are similar to those observed with therapeutic modalities [12,24].”
Rieser, N. M., Gubser, L. P., Moujaes, F., Duerler, P., Lewis, C. R., Michels, L., Vollenweider, F. X., & Preller, K. H. (2023) · Scientific Reports · doi:10.1038/s41598-023-44153-z · Cited by 21
Wang, S., Kim, S., Choi, W.-S., Lim, H. K., Woo, Y. S., Pae, C., & Bahk, W. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1134 · Cited by 21
“The first DB-RCT in MDD per se was conducted by Carhart-Harris et al. [37], and it compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a 6-week period.”
BackgroundMethodPsychedelics, OCD and related disorders: A systematic review
Graziosi, M., Rohde, J. S., Tiwari, P., Siev, J., & Yaden, D. B. (2024) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2024.100873 · Cited by 22
Effects of Psychedelics in Older Adults: A Prospective Cohort Study
Kettner, H., Roseman, L., Gazzaley, A. H., Carhart-Harris, R. L., & Pasquini, L. (2024) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2024.05.007 · Cited by 21
“10,11 On the contrary, their use has been associated with an increased incidence of adverse respiratory and gastrointestinal events, as well as emotional blunting when compared to placebo, 10 − 12 highlighting the need for improved treatments for affective symptoms in OA.”
BackgroundSelf-citationLappas, A. S., Glarou, E., Polyzopoulou, Z. A., Goss, G., Huhn, M., Samara, M. T., & Christodoulou, G. N. (2024) · Sleep Medicine · doi:10.1016/j.sleep.2024.05.032 · Cited by 21
Campanale, A., Inserra, A., & Comai, S. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111058 · Cited by 20
Barrett, F. S., Zhou, Y., Carbonaro, T. M., Roberts, J., Smith, G. S., Griffiths, R. R., & Wong, D. F. (2022) · Frontiers in Neuroergonomics · doi:10.3389/fnrgo.2021.784576 · Cited by 21
A Bayesian Reanalysis of a Trial of Psilocybin Versus Escitalopram for Depression
Nayak, S. M., Bari, B. A., Yaden, D. B., Spriggs, M. J., Rosas, F. E., Peill, J. M., Giribaldi, B., Erritzøe, D., Nutt, D. J., & Carhart-Harris, R. L. (2022) · Psychedelic Medicine · doi:10.1089/psymed.2022.0002 · Cited by 23
“Notably, psilocybin’s adverse effects tended to be limited to the 24 h after the dosing sessions, in contrast to escitalopram.(1) Thus, even if psilocybin were noninferior but not superior to escitalopram, it may have a more favorable risk–benefit ratio.”
BackgroundResultSelf-citationPsychedelics for Patients With Cancer: A Comprehensive Literature Review
White, C. M., Weisman, N., & Dalo, J. D. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280221144055 · Cited by 19
Kalkman, H. O. (2023) · Biomedicines · doi:10.3390/biomedicines11030806 · Cited by 18
Further education in psychedelic-assisted therapy – experiences from Switzerland
Aicher, H., Müller, F., & Gasser, P. (2025) · BMC Medical Education · doi:10.1186/s12909-025-06871-y · Cited by 20
“Recent clinical trials have demonstrated promising results for psychedelics and MDMA in the treatment of various psychiatric disorders, including treatment-resist-ant depression, post-traumatic stress disorder (PTSD), and anxiety disorders [10, 19, 21, 29, 30, 41, 49, 56, 63].”
New trends in pharmacological control of neuropsychiatric symptoms of dementia
Scuteri, D., Corasaniti, M. T., Tonin, P., Nicotera, P., & Bagetta, G. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.09.002 · Cited by 19
Body mass index (BMI) does not predict responses to psilocybin
Spriggs, M. J., Giribaldi, B., Lyons, T., Rosas, F. E., Kärtner, L., Buchborn, T., Douglass, H. M., Roseman, L., Timmermann, C., Erritzøe, D., et al. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221131994 · Cited by 22
Self-citationLinguiti, S., Vogel, J. W., Sydnor, V. J., Pines, A. R., Wellman, N., Basbaum, A. I., Eickhoff, C. R., Eickhoff, S. B., Edwards, R. R., Larsen, B., et al. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105421 · Cited by 26
Liu, G., Ma, L., Qu, Y., Wan, X., Xu, D., Zhao, M., Murayama, R., & Hashimoto, K. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173659 · Cited by 19
Effects of Ayahuasca on Gratitude and Relationships with Nature: A Prospective, Naturalistic Study
Aday, J. S., Bloesch, E. K., Davis, A. K., Domoff, S. E., Scherr, K. C., Woolley, J. D., & Davoli, C. C. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2312980 · Cited by 20
“…of high scientific, public, and regulatory interest because of the promising therapeutic effects that have been demonstrated in clinical trials when the drugs are paired with psychotherapeutic support (Aday, Carhart-Harris, and Woolley 2023; Anderson et al. 2020; Carhart-Harris et al. 2021).”
BackgroundPsychedelics and Evidence-based Psychotherapy
Leone, L., McSpadden, B., DeMarco, A., Enten, L., Kline, R., & Fonzo, G. A. (2024) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2024.02.006 · Cited by 19
Psychedelics and disorders of consciousness: the current landscape and the path forward
Cardone, P., Alnagger, N., Annen, J., Bicego, A., Gosseries, O., & Martial, C. (2024) · Neuroscience of Consciousness · doi:10.1093/nc/niae025 · Cited by 20
Jager, J. E. D., Boesjes, R., Roelandt, G. H. J., Koliaki, I., Sommer, I. E., Schoevers, R. A., & Nuninga, J. O. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105796 · Cited by 21
Experiential Training in Psychedelic‐Assisted Therapy: A Risk‐Benefit Analysis
Rosenbaum, D., Hare, C., Hapke, E., Herman, Y., Abbey, S. E., Sisti, D. A., & Buchman, D. Z. (2024) · The Hastings Center Report · doi:10.1002/hast.1602 · Cited by 20
Psychedelic risks and benefits: A cross-sectional survey study
Goldy, S. P., Du, B. A., Rohde, J. S., Nayak, S. M., Strickland, J. C., Ehrenkranz, R. C., Levine, M., Barrett, F. S., & Yaden, D. B. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241292951 · Cited by 19
“Studies of these substances have demonstrated preliminary evidence of potential benefits for several conditions, including major depressive disorder (Carhart-Harris et al., 2016, 2021; Davis et al., 2021; D’Souza et al., 2022; Goodwin et al., 2023; Raison et al., 2023), end-of-life anxiety and…”
Concurrent stress modulates the acute and post-acute effects of psilocybin in a sex-dependent manner
Farinha‐Ferreira, M., Miranda‐Lourenço, C., Galipeau, C., Lenkei, Z., & Sebastião, A. M. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110280 · Cited by 20
Mice lacking the serotonin transporter do not respond to the behavioural effects of psilocybin
Gattuso, J. J., Wilson, C., Li, S., Hannan, A. J., & Renoir, T. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177304 · Cited by 18
Parental Attitudes Toward Use of Ketamine in Adolescent Mood Disorders and Suicidality
Mathai, D. S., McCathern, A. G., Guzick, A. G., Schneider, S. C., Weinzimmer, S. A., Cepeda, S. L., Garcia‐Romeu, A., & Storch, E. A. (2021) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2021.0078 · Cited by 19
Ledwos, N., Rosenblat, J. D., Blumberger, D. M., Castle, D. J., McIntyre, R. S., Mulsant, B. H., & Husain, M. I. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001608 · Cited by 20
Cellular rules underlying psychedelic control of prefrontal pyramidal neuronsPreprint
Ekins, T. G., Brooks, I. A. W., Kailasa, S., Rybicki-Kler, C., Jedrasiak‐Cape, I., Donoho, E., Mashour, G. A., Rech, J. C., & Ahmed, O. J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.20.563334 · Cited by 24
Is good science leading the way in the therapeutic use of psychedelic drugs?
Hall, W. D., & Humphreys, K. (2022) · Psychological Medicine · doi:10.1017/s0033291722003191 · Cited by 17
“…of Medicine recently published a phase 2, randomized, controlled trial comparing the effects of psilocybin with those of a selective serotonin-reuptake inhibitor, escitalopram, in treating patients with long-standing major depressive disorder over a 6-week period (Carhart-Harris et al., 2021).”
BackgroundSet and setting of psychedelics for therapeutic use in psychiatry: A systematic review
Estric, C., Duron, T., Kabani, S., & López‐Castromán, J. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251338214 · Cited by 19
“…the participant did not drive a vehicle within 24 h of the psychedelic administration by staying in hospital (Gasser et al., 2014), ordering a taxi (Carhart-Harris et al., 2021) or requiring a family member or close relative to collect the participant (Aaronson et al., 2023; Carhart-Harris et al.,…”
InfluentialA systematic review of income and education reporting in psychedelic clinical trials
Grossman, D. H., Madden, K. R., Mehtani, N. J., Anderson, B. T., Davis, L. L., Mitchell, J., & Hendricks, P. S. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00417-3 · Cited by 17
Psychedelics, entactogens and psychoplastogens for depression and related disorders
Hoyer, D. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70088 · Cited by 18
Hultgren, J., Hafsteinsson, M. H., & Brulin, J. G. (2025) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2025.07.020 · Cited by 17
Bloch, Y., Belmaker, R. H., Shvartzman, P., Romem, P., Bolotin, A., Bersudsky, Y., & Azab, A. N. (2021) · Scientific Reports · doi:10.1038/s41598-021-98245-9 · Cited by 17
Behavioral Psychedelics: Integrating Mind and Behavior to Improve Health and Resilience
Neuhaus, E. C., & Slavich, G. M. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.821208 · Cited by 17
“Additionally, a recent Phase 2 clinical trial of the psychedelic compound psilocybin reduced depression when combined with psychotherapy (5).”
BackgroundModerators of ayahuasca’s biological antidepressant action
de Sousa, G. M., Tavares, V. D. D. O., Galvão, A. C. D. M., de Almeida, R. N., Palhano-Fontes, F., Soares, B. L., Freire, F. A. D. M., Nunes, E. A., Maia‐de‐Oliveira, J. P., Perkins, D., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1033816 · Cited by 26
Impact of a Naturalistic Psychedelic Experience on Smoking: A Retrospective Survey
Roméo, B., Fauvel, B., Dejean, S., Strika-Bruneau, L., Amirouche, A., Verroust, V., Piolino, P., & Benyamina, A. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2227171 · Cited by 17
“Studies have been conducted in the field of treatment-resistant depression (Carhart-Harris et al. 2016, 2021; Palhano-Fontes et al. 2019), but also of addiction, such as tobacco (Johnson et al. 2014; Johnson, Garcia-Romeu, and Griffiths 2017) or alcohol use disorder (Bogenschutz et al. 2015, 2022).”
Neural Geometrodynamics, Complexity, and Plasticity: A Psychedelics Perspective
Ruffini, G., Lopez-Sola, E., Vohryzek, J., & Sanchez-Todo, R. (2024) · Entropy · doi:10.3390/e26010090 · Cited by 21
Brain Networks, Neurotransmitters and Psychedelics: Towards a Neurochemistry of Self-Awareness
Mograbi, D. C., Rodrigues, R. F. S., Bienemann, B., & Huntley, J. D. (2024) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-024-01353-y · Cited by 22
“…act mainly through changes in DMN, which would explain the therapeutic effects observed particularly in conditions with excessive DMN functioning (e.g. psilocybin for depression, [14]), and is also in line with more consistent changes in narrative features of self-awareness, as described here.”
BackgroundSalvetti, G., Saccenti, D., Moro, A. S., Lamanna, J., & Ferro, M. (2024) · Brain Sciences · doi:10.3390/brainsci14080829 · Cited by 18
Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs
Borgogna, N. C., Owen, T., Petrovitch, D., Vaughn, J., Johnson, D. A., Pagano, L. A., Aita, S. L., & Hill, B. D. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06788-w · Cited by 20
“They compared brain states using fMRI in participants from Carhart-Harris et al. (2021).”
Toward the “helioscope” hypothesis of psychedelic therapy
Hasler, G. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.02.006 · Cited by 17
Prevalence and associations of classic psychedelic-related seizures in a population-based sample
Simonsson, O., Goldberg, S. B., Chambers, R., Osika, W., Long, D. M., & Hendricks, P. S. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109586 · Cited by 17
“These psychoactive compounds, which exert effects through agonist activity at the serotonin 2A receptor, have recently received renewed scientific attention (Nutt and Carhart-Harris, 2021).”
BackgroundChanged Substance Use After Psychedelic Experiences Among Individuals in Canada
Boehnke, K. F., Kruger, D. J., & Lucas, P. (2023) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-023-01085-z · Cited by 20
Avram, M., Müller, F., Preller, K. H., Razi, A., Rogg, H. V., Korda, A. I., Holze, F., Vizeli, P., Ley, L., Liechti, M. E., et al. (2023) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2023.07.010 · Cited by 24
Berkovitch, L., Fauvel, B., Preller, K. H., & Gaillard, R. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106239 · Cited by 17
Mechanistic intersections between migraine and major depressive disorder
Johnson, M., Filali, Y., Adegboyo, A., Eberle, M., Townsend, A., Hussien, Y., Marcinkiewcz, C. A., & Hultman, R. C. (2025) · The Journal of Headache and Pain · doi:10.1186/s10194-025-02097-x · Cited by 17
New and emerging pharmacologic treatments for MDD
Uyar, A., & Gönül, A. S. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1621887 · Cited by 20
Psychedelic-assisted therapy as a complex intervention: implications for clinical trial design
Muthukumaraswamy, S. D., Baggott, M. J., Schenberg, E. E., Repantis, D., Wolff, M., Forsyth, A., & Noorani, T. N. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251381074 · Cited by 25
“For example, trial publications often present schematics of the ‘ideal’ trial for participants – specifying the exact number of 18 several phase II trials of psilocybin for depression 40–42 and a phase II trial of LSD for anxiety.”
Postpartum depression: A role for psychedelics?
Jairaj, C., & Rucker, J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221093793 · Cited by 17
“A phase 2, double-blind RCT comparing psilocybin with the SSRI escitalopram in a cohort of 59 participants with moderate-to-severe MDD was recently reported (Carhart-Harris et al., 2021).”
BackgroundPredictors of attitudes toward psychedelics among psychologists in the USA
Luoma, J. B., Pilecki, B. C., Davis, A. K., & Smith, S. M. (2022) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2022.2117022 · Cited by 17
“…anxiety, treatment-resistant depression, major depressive disorder, and substance use disorders (Agin-Liebes et al., 2020; Bogenschutz et al., 2015; Carhart-Harris et al., 2021; Davis, Barrett, et al., 2021; Garcia-Romeu et al., 2019; Griffiths et al., 2016; Luoma et al., 2020; Swift et al.,…”
BackgroundProphylactic action of ayahuasca in a non-human primate model of depressive-like behavior
Grilo, M. L. P. D. M., de Sousa, G. M., de Mendonça, L. A. C., Soares, B. L., de Sousa, M. B. C., Palhano-Fontes, F., de Araújo, D. B., Perkins, D., Hallak, J. E. C., & Coelho, N. L. G. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.901425 · Cited by 18
“The frequency of ayahuasca administration used in this study was based on an average frequency of ayahuasca consumption in Brazilian religious rituals and psychedelicbased psychotherapy models (Carhart-Harris et al., 2021).”
MethodMuthukumaraswamy, S. D. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2279736 · Cited by 20
“Still in clinical development, MDMA-assisted psychotherapy for the treatment of PTSD has two published Phase 3 clinical trials [2] and several Phase 2 trials for psilocybin in treatment-resistant depression have been conducted [3–6], with a Phase 3 program underway [7].”
BackgroundBreau, J. A., & Gillis‐Smith, P. (2023) · Interdisciplinary Science Reviews · doi:10.1080/03080188.2023.2266322 · Cited by 16
“As psychedelics have received immense support in psychiatric research as treatments for alcoholism (Bogenschutz et al. 2022), depression (Carhart-Harris et al. 2021; Palhano-Fontes et al. 2019), tobacco addiction (Johnson et al. 2014), and other mental health conditions (Gri ffi ths et al. 2016; Ross…”
BackgroundSynthetic surprise as the foundation of the psychedelic experience
Filippo, R. D., & Schmitz, D. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105538 · Cited by 19
Arias, H. R., Rudin, D., Hines, D. J., Contreras, A., Gulsevin, A., Manetti, D., Anouar, Y., Deurwaerdère, P. D., Meiler, J., Romanelli, M. N., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176329 · Cited by 18
Diminished psychedelic returns on distress: Marital status and household size
Viña, S. M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0293675 · Cited by 18
Metadata
- Authors
- Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J.
- Affiliations
- Imperial College London (GB)
- From the Centre for Psychedelic Research, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-04-15
- Volume
- 384
- Issue
- 15
- Pages
- 1402-1411
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3156937150
- Cited by
- 1,391
- References
- 26
- Citations by year
- 2026: 200 · 2025: 278 · 2024: 287 · 2023: 284 · 2022: 247 · 2021: 92
- FWCI
- 154.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alex Mosley Charitable Trust (NA)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- psilocybin, escitalopram, major depressive disorder, antidepressant efficacy, psychedelic therapy, selective serotonin reuptake inhibitors, depression remission, treatment-resistant depression, psychological support, hallucinations, dissociation, synesthesia, anxiety disorders
- MeSH terms
- Adult, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Female, Hallucinogens, Humans, Male, Middle Aged, Psilocybin, Surveys and Questionnaires, Citalopram, Antidepressive Agents, Second-Generation, Young Adult, Self Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.